Trust Co. of Vermont Boosts Stock Holdings in Stryker Corporation $SYK

Key Points

• Trust Co. of Vermont increased its stake in Stryker Corporation by 2.4%, owning 32,393 shares valued at approximately $12.8 million.
• Stryker reported earnings of $3.13 per share for the last quarter, exceeding analyst expectations, with revenue of $6.02 billion, up 11.1% year-over-year.
• The company announced a quarterly dividend of $0.84 per share, with an ex-dividend date of September 30th, indicating a dividend yield of 0.9%.

Trust Co. of Vermont increased its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 2.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,393 shares of the medical technology company's stock after purchasing an additional 750 shares during the period. Trust Co. of Vermont's holdings in Stryker were worth $12,816,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Goodman Advisory Group LLC purchased a new position in Stryker in the first quarter valued at about $32,000. City Holding Co. increased its holdings in Stryker by 528.6% in the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after buying an additional 74 shares in the last quarter. Ridgewood Investments LLC increased its holdings in Stryker by 48.4% in the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company's stock valued at $36,000 after buying an additional 30 shares in the last quarter. Ransom Advisory Ltd purchased a new position in Stryker in the first quarter valued at about $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in Stryker in the first quarter valued at about $40,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Performance

Shares of SYK stock opened at $369.44 on Wednesday. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The firm has a market capitalization of $141.24 billion, a P/E ratio of 48.93, a P/E/G ratio of 2.67 and a beta of 0.93. The company's fifty day moving average price is $384.81 and its two-hundred day moving average price is $379.11.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping analysts' consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm's revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker's payout ratio is presently 44.50%.

Insider Activity

In other news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Viju Menon sold 500 shares of the business's stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company's stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SYK. Rothschild & Co Redburn assumed coverage on shares of Stryker in a report on Thursday, September 18th. They issued a "neutral" rating and a $420.00 target price for the company. Rothschild Redb raised shares of Stryker to a "hold" rating in a research note on Thursday, September 18th. Needham & Company LLC raised their price objective on shares of Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. BTIG Research reissued a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Finally, Redburn Partners set a $420.00 price objective on shares of Stryker in a research note on Thursday, September 18th. Fourteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Stryker has an average rating of "Moderate Buy" and a consensus target price of $430.33.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.